Novartis' Drug Pipeline and Valuation Premium Under Scrutiny
Investors will closely watch Novartis for signs of success in three major drug trials due later this year, which are critical to justifying the company's premium valuation. The experimental drugs—pelacarsen, remibrutinib, and del-desiran—are seen as key growth drivers amid looming patent expiries.
Topics: clinical trials patent expiries pipeline valuation R&D focus